Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
LUXEMBOURG--(BUSINESS WIRE)-- Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing announces the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a market leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET*, and chemistry services for integrated drug discovery solutions. The transaction is expected to close in the coming weeks upon fulfilment of customary closing conditions.
Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development as well as their profound expertise in GPCR research, complemented by their unique compound library. The addition of Beacon Discovery supports Eurofins’ strategy to be the partner of choice to the pharmaceutical industry, providing drug discovery experience, knowledge, and proven success in supporting the discovery and development of new therapeutics. Beacon Discovery significantly augments Eurofins Discovery’s capabilities and innovative methods to support and accelerate drug discovery research and development and capitalize on the growing R&D outsourcing market.
Comment from Dr. Sunny Al-Shamma, Beacon Discovery’s CEO: “Beacon Discovery is very excited to join Eurofins. Joining the Eurofins Discovery organisation expands our opportunity to continue our drug discovery efforts and provide integrated drug discovery services with the additive and complementary capabilities provided by Eurofins Discovery”.
Comment from Dr. Gilles Martin, Eurofins’ CEO: “Beacon Discovery adds the expertise in GPCR targets and drug discovery and development experience that will advance our offering in integrated drug discovery services for our clients. This transaction is another demonstration of Eurofins’ commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend.
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
Eurofins Scientific SE
Phone: +32 2 766 1620
Source: Eurofins Scientific
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Residential Investment Corp. Announces Pricing of Public Offering of Common Stock
- FRMO Corp. Announces Third Quarter Results and Conference Call
- AG&P Construction Wins Over US$770 Million in Contracted Backlog
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!